Vor Biopharma Inc. (VOR): Nasdaq/NYSE listing notice — Vor Biopharma receives Nasdaq notice for non-compliance with $1.00 minimum bid price rule

Vor Biopharma Inc.

Notice received April 22, 2025; stock below $1.00 for 30 consecutive business days.
Company has 180 calendar days (until Oct 20, 2025) to regain compliance.
To cure, bid price must close at $1.00+ for 10 consecutive business days.
May transfer to Nasdaq Capital Market for an additional 180-day grace period if needed.
If not cured, stock faces potential delisting; company is evaluating options.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Vor Biopharma Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

April 22, 2025, Vor Biopharma Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market. The Company has 180 calendar days, or until October 20, 2025, to regain compliance with the minimum bid price requirement. To regain compliance

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Vor Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-096692

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.